Sayad Arezou, Hajifathali Abbas, Hamidieh Amir Ali, Esfandi Farbod, Taheri Mohammad
Department of Medical Genetics, Shahid Beheshti University of Medical sciences, Tehran, Iran. Email:
Asian Pac J Cancer Prev. 2018 Jan 27;19(1):45-48. doi: 10.22034/APJCP.2018.19.1.45.
In recent years, lncRNAs have been considered as potential predictive biomarkers for prognosis of different human cancers. One example is the FAS antisense RNA 1 (FAS-AS1) located in the 10q23.31 region which is transcribed from the opposite strand of the FAS gene. FAS has an important role in regulation of apoptotic pathways and there is an inverse correlation between FAS-AS1 expression level and production of the soluble form of Fas, so that it might have potential as a therapeutic target to improve chemotherapy effectiveness. In the present study we therefore evaluated FAS-AS1 expression in blood samples of de novo AML patients and healthy controls using real-time quantitative reverse transcription-PCR (qRT-PCR). Our results indicated that the expression level of FAS-AS1 lncRNA demonstrated no significant difference between AML patients and healthy individuals. We conclude from the obtained data that FAS-AS1 is not an informative and reliable biomarker for AML diagnosis, although our results need to be confirmed in further studies.
近年来，长链非编码RNA（lncRNAs）被认为是不同人类癌症预后的潜在预测生物标志物。一个例子是位于10q23.31区域的FAS反义RNA 1（FAS-AS1），它从FAS基因的反义链转录而来。FAS在凋亡途径的调节中起重要作用，并且FAS-AS1表达水平与可溶性Fas形式的产生呈负相关，因此它可能具有作为改善化疗效果的治疗靶点的潜力。因此，在本研究中，我们使用实时定量逆转录PCR（qRT-PCR）评估了初发急性髓系白血病（AML）患者和健康对照者血液样本中FAS-AS1的表达。我们的结果表明，FAS-AS1 lncRNA的表达水平在AML患者和健康个体之间没有显著差异。我们从获得的数据中得出结论，FAS-AS1不是AML诊断的信息丰富且可靠的生物标志物，尽管我们的结果需要在进一步研究中得到证实。
